When is targeted therapy recommended for chronic lymphocytic leukaemia?

Some people with CLL are monitored without immediate treatment when the disease is stable and symptoms are limited. Treatment may be discussed when there is troublesome or worsening disease, such as significant tiredness, enlarged lymph nodes or spleen, falling blood counts, or symptoms caused by the leukaemia. Blood tests, examination and sometimes imaging help show the pattern.

Targeted medicines act on proteins or pathways used by CLL cells. Choice depends on chromosome and molecular findings, kidney and heart health, other medicines, bleeding risk and whether this is initial treatment or treatment after the disease has returned. The team will balance control of CLL with side-effect risks.

Keep a record of infections, bruising, bleeding, night sweats, weight change and changes in energy. Bring every medicine and supplement to appointments; some targeted medicines interact with common drugs. Ask which blood tests, scans or molecular tests guide the choice and how often monitoring is needed.

Take treatment at the prescribed time and follow instructions about food. Do not stop suddenly or double a missed dose unless your team tells you what to do. Vaccination and infection-prevention advice should be individualised.

Tell your CLL team promptly about fever, chills, a new infection, unusual bleeding, rapidly enlarging nodes, severe headache or breathlessness. Seek urgent care for uncontrolled bleeding, severe breathing trouble, fainting or sudden confusion. These symptoms can reflect infection, low blood counts or another complication.

Ask: Does my CLL need treatment now? Which disease feature supports this medicine? How does it compare with other options? What interactions should we check? Which symptoms require a same-day call, and when will we review the response?